Exploring the inner life of GPCRs to create and tailor new therapeutics for endocrine disorders and endocrine-related cancers.
WE ARE CRINETICS
Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Location: United States, California, San Diego
Employees: 51-200
Phone: (858) 450-6464
Total raised: $106.3M
Founded date: 2008
Investors 5
Date | Name | Website |
- | 5AM Ventur... | 5amventure... |
- | RA Capital... | racap.com |
- | OrbiMed | orbimed.co... |
- | Perceptive... | perceptive... |
- | Vivo Capit... | vivocapita... |
Funding Rounds 3
Date | Series | Amount | Investors |
17.03.2018 | Series B | $63.5M | - |
13.07.2017 | Grant | $2.8M | - |
20.11.2015 | Series A | $40M | - |
Mentions in press and media 20
Date | Title | Description | Source |
12.03.2024 | Crinetics Announces Positive Topline Results from Phase 2 Tr... | Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flush... | einpresswi... |
11.03.2024 | Crinetics Pharmaceuticals Announces March 2024 Inducement Gr... | - | globenewsw... |
11.03.2024 | Crinetics Pharmaceuticals Announces March 2024 Inducement Gr... | SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today a... | einpresswi... |
28.02.2024 | Crinetics Pharmaceuticals Reports Fourth Quarter and Full Ye... | Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in ... | einpresswi... |
17.08.2023 | Startup is developing a pill intended to help large dogs liv... | San Francisco-based Loyal is working on a new drug it hopes will help large dogs live healthier, lon... | axios.com/... |
04.05.2023 | Pioneering Pharmaceutical Company Supports Next Generation w... | TOOTRiS Child Care On-Demand TOOTRiS Child Care On-Demand and Crinetics Pharmaceuticals partner to p... | einpresswi... |
12.01.2022 | Crinetics Pharmaceuticals to Present Corporate and Clinical ... | - Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 – - Initiation ... | marketscre... |
28.10.2021 | Radionetics Oncology Launches with $30M Investment | Photo Courtesy of Crinetics San Diego-based Crinetics Pharmaceuticals focuses on discovery, developm... | sdbj.com/n... |
25.10.2021 | Crinetics Pharmaceuticals : Announces Closing of Public Offe... | SAN DIEGO - October 25, 2021 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage phar... | marketscre... |
06.05.2021 | CRINETICS PHARMACEUTICALS, INC. Crinetics Pharmaceuticals R... | Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 an... | marketscre... |
Show more